Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Adherium Ltd. ( (AU:ADR) ) has issued an announcement.
Adherium Ltd. has applied to the ASX for quotation of 27,734,391 new fully paid ordinary shares, to be issued on March 19, 2026. The application, lodged as an Appendix 2A, follows previously announced transactions and will expand the company’s quoted share capital, potentially enhancing liquidity and supporting ongoing corporate and operational initiatives.
The additional securities arise from transactions earlier disclosed via an Appendix 3B, indicating progression from capital-raising or related corporate activities into formal quotation. This move may strengthen Adherium’s balance sheet and market presence, providing further resources for its digital health strategy and offering existing and new investors increased tradable stock.
The most recent analyst rating on (AU:ADR) stock is a Sell with a A$0.01 price target. To see the full list of analyst forecasts on Adherium Ltd. stock, see the AU:ADR Stock Forecast page.
More about Adherium Ltd.
Adherium Ltd. is an Australia-based medical technology company listed on the ASX under the code ADR. The company develops and supplies digital health solutions, including connected devices and platforms aimed at improving medication adherence and respiratory disease management in healthcare markets.
Technical Sentiment Signal: Sell
Current Market Cap: A$13.03M
See more data about ADR stock on TipRanks’ Stock Analysis page.